Robeco Institutional Asset Management B.V. reduced its position in shares of UnitedHealth Group Incorporated (NYSE:UNH) by 3.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 427,830 shares of the healthcare conglomerate’s stock after selling 15,609 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in UnitedHealth Group were worth $83,789,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of UNH. Blue Chip Partners Inc. purchased a new stake in shares of UnitedHealth Group during the second quarter worth about $110,000. Kings Point Capital Management lifted its holdings in UnitedHealth Group by 27.9% in the first quarter. Kings Point Capital Management now owns 687 shares of the healthcare conglomerate’s stock worth $113,000 after buying an additional 150 shares during the period. Bruderman Asset Management LLC purchased a new stake in UnitedHealth Group in the second quarter worth about $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its holdings in UnitedHealth Group by 433.3% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 640 shares of the healthcare conglomerate’s stock worth $119,000 after buying an additional 520 shares during the period. Finally, BDO Wealth Advisors LLC purchased a new stake in UnitedHealth Group in the second quarter worth about $121,000. Institutional investors own 86.20% of the company’s stock.
Shares of UnitedHealth Group Incorporated (NYSE UNH) opened at $221.82 on Monday. The firm has a market cap of $214,958.67, a P/E ratio of 23.11, a P/E/G ratio of 1.65 and a beta of 0.66. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 0.52. UnitedHealth Group Incorporated has a 1 year low of $156.09 and a 1 year high of $231.77.
UnitedHealth Group (NYSE:UNH) last announced its quarterly earnings results on Tuesday, October 17th. The healthcare conglomerate reported $2.66 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.57 by $0.09. The company had revenue of $50.32 billion during the quarter, compared to the consensus estimate of $50.38 billion. UnitedHealth Group had a net margin of 4.50% and a return on equity of 21.52%. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter last year, the firm earned $2.17 earnings per share. research analysts forecast that UnitedHealth Group Incorporated will post 9.99 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Friday, December 1st were given a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a dividend yield of 1.35%. The ex-dividend date was Thursday, November 30th. UnitedHealth Group’s dividend payout ratio (DPR) is currently 33.26%.
In other UnitedHealth Group news, Director Gail R. Wilensky sold 5,600 shares of UnitedHealth Group stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $223.31, for a total value of $1,250,536.00. Following the completion of the sale, the director now owns 61,137 shares of the company’s stock, valued at approximately $13,652,503.47. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Kenneth Irwin Shine sold 457 shares of UnitedHealth Group stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $211.03, for a total transaction of $96,440.71. The disclosure for this sale can be found here. Insiders have sold 12,032 shares of company stock valued at $2,658,310 in the last three months. 0.89% of the stock is owned by insiders.
Several analysts have commented on the stock. Leerink Swann restated a “buy” rating and issued a $240.00 price objective (up from $225.00) on shares of UnitedHealth Group in a report on Wednesday, October 18th. Zacks Investment Research upgraded shares of UnitedHealth Group from a “hold” rating to a “buy” rating and set a $219.00 price objective for the company in a report on Thursday, September 21st. Cantor Fitzgerald raised their price objective on shares of UnitedHealth Group to $225.00 and gave the stock an “overweight” rating in a report on Wednesday, October 18th. Oppenheimer raised their price objective on shares of UnitedHealth Group from $215.00 to $205.00 and gave the stock an “outperform” rating in a report on Wednesday, October 18th. Finally, Wells Fargo & Company restated an “outperform” rating and issued a $245.00 price objective (up from $230.00) on shares of UnitedHealth Group in a report on Wednesday, November 29th. Three equities research analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $224.56.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/18/robeco-institutional-asset-management-b-v-has-83-79-million-stake-in-unitedhealth-group-incorporated-unh.html.
About UnitedHealth Group
UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.